BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. MU
6. SPY
7. KBH
8. HTZ
9. HON
10. PFE

Go back to BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.37 +0.11 (3.37%)
Previous Close $3.26    52 Week High $1.63 
Open $3.20    52 Week Low $0.71 
Day High $3.49    P/E N/A 
Day Low $3.10    EPS $0.00 
Volume 24,394       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.37 +0.11 (3.37%)
Previous Close $3.26    52 Week High $1.63 
Open $3.20    52 Week Low $0.71 
Day High $3.49    P/E N/A 
Day Low $3.10    EPS $0.00 
Volume 24,394